15th week of 2014 patent applcation highlights part 39 |
Patent application number | Title | Published |
20140100108 | HERBICIDALLY AND FUNGICIDALLY ACTIVE 3-PHENYLISOXAZOLINE-5-CARBOXAMIDES AND 3-PHENYLISOXAZOLINE-5-THIOAMIDES - 3-Phenylisoxazoline-5-carboxamides and 3-phenylisoxazoline-5-thioamides of the formula (I) and their use as herbicides and fungicides are described. | 2014-04-10 |
20140100109 | SAFENING COMPOSITION OF 6-(TRISUBSTITUDED PHENYL)-4-AMINO-2-PYRIDINECARBOXYLATE HERBICIDES AND CLOQUINTOCET-MEXYL FOR CEREAL CROPS - Herbicidal injury caused by 6-trisubstituted phenyl)-4-amino-2-pyridinecarboxylates in wheat and barley is reduced with the use of low rates of cloquintocet. | 2014-04-10 |
20140100110 | Soybean Event DP-305423-1 And Compositions And Methods For The Identification And/Or Detection Thereor - Compositions and methods related to transgenic high oleic acid/ALS inhibitor-tolerant soybean plants are provided. Specifically, the present invention provides soybean plants having a DP-305423-1 event which imparts a high oleic acid phenotype and tolerance to at least one ALS-inhibiting herbicide. The soybean plant harboring the DP-305423-1 event comprises genomic/transgene junctions having at least the polynucleotide sequence of SEQ ID NO:8, 9, 14, 15, 20, 21, 83 or 84. The characterization of the genomic insertion site of the DP-305423-1 event provides for an enhanced breeding efficiency and enables the use of molecular markers to track the transgene insert in the breeding populations and progeny thereof. Various methods and compositions for the identification, detection, and use of the soybean DP-305423-1 events are provided. | 2014-04-10 |
20140100111 | Seed Coating Hydrogels - A bio-degradeable seed coating composition for enhanced seed protection and propagation comprises a gelatin-based hydrogel formulation consisting of a naturally derived, hydrophilic protein in combination with a sulfated or non-sulfated polysaccharide. The protein is animal porcine or bovine derived while the polysaccharide is preferably a cellulose derivative such as sodium cellulose sulfate, dextran sulfate, sulfated chitosan, sulfated starch and mixtures thereof. The seed coating composition may also comprise a rheology modifier comprising a clay, a dessicant or silica gel. | 2014-04-10 |
20140100112 | ELECTRODEPOSITION OF BIAXIALLY TEXTURED LAYERS ON A SUBSTRATE - Methods of producing one or more biaxially textured layer on a substrate, and articles produced by the methods, are disclosed. As exemplary method may comprise electrodepositing on the substrate a precursor material selected from the group consisting of rare earths, transition metals, actinides, lanthanides, and oxides thereof. An exemplary article may comprise a biaxially textured base material, and at least one biaxially textured layer selected from the group consisting of rare earths, transition metals, actinides, lanthanides, and oxides thereof. The at least one biaxially textured layer is formed by electrodeposition on the biaxially textured base material. | 2014-04-10 |
20140100113 | REMOTE ACTUATED CRYOCOOLER FOR SUPERCONDUCTING GENERATOR AND METHOD OF ASSEMBLING THE SAME - In one embodiment, a cryocooler assembly for cooling a heat load is provided. The cryocooler assembly includes a vacuum vessel surrounding the heat load and a cryocooler at least partially inserted into the vacuum vessel, the cryocooler including a coldhead. The assembly further includes an actuator coupled to the cryocooler. The actuator is configured to translate the cryocooler coldhead into thermal engagement with the heat load and to maintain constant pressure of the coldhead against the heat load to facilitate maintaining thermal engagement with the heat load as the heat load shrinks during a cool down process. | 2014-04-10 |
20140100114 | COOLING ASSEMBLY FOR ELECTRICAL MACHINES AND METHODS OF ASSEMBLING THE SAME - A cryocooler assembly for cooling a field winding of an electrical machine having an axis of rotation is provided. The assembly includes a cryocooler and a reservoir coupled in flow communication to the cryocooler and configured to contain a cooling agent. A flow assembly is coupled in flow communication to the reservoir. The flow assembly includes a first flow loop coupled in flow communication to the reservoir; a second flow loop coupled in flow communication to the reservoir; and a plurality of flow members coupled in flow communication to the first flow loop and the second flow loop and coupled to the field winding. Each flow member is configured to thermosiphon the cooling agent in a first state from the reservoir and in a second state to the reservoir. | 2014-04-10 |
20140100115 | ROTOR FOR AN ELECTRIC MACHINE AND ELECTRIC MACHINE - A rotor for an electric machine includes a pole core having a coolable magnetisable rotor section which is made of a super-conducting material. The rotor section has a rotationally symmetric geometry. The pole core is formed as a cylinder and the rotor section is arranged on an outer surface of the cylinder so as to be encircling. | 2014-04-10 |
20140100116 | Inductive fault current limiter with divided secondary coil configuration - An inductive fault current limiter ( | 2014-04-10 |
20140100117 | Method for producing a superconducting wire, in particular using lead-free solder - A method for producing a superconducting wire ( | 2014-04-10 |
20140100118 | METHOD FOR CONTINUOUSLY FORMING SUPERCONDUCTING WIRE AND PRODUCTS THEREFROM - A device and method for continuously forming superconducting wire, and products made therefrom. The method may include providing at least one continuous metal sheathing strip and at least one metal form, continuously forming the at least one continuous metal sheathing strip to form a partially open configuration, continuously filling the partially open configuration with magnesium diboride precursor comprising boron, and a metal form, and closing the partially open configuration thereby enclosing the magnesium diboride precursor comprising boron, and a metal form, to form a closed configuration. Subsequent reduction in diameter and elongation in length of the closed configuration, followed by heat treatment, catalyzes the transformation of the magnesium diboride precursor comprising boron, and the metal form, to magnesium diboride to form the superconducting wire. | 2014-04-10 |
20140100119 | Superconducting structure having linked band-segments which are each overlapped by directly sequential additional band-segments - A superconducting structure ( | 2014-04-10 |
20140100120 | METHODS OF X-APTAMER GENERATION AND COMPOSITIONS THEREOF - Provided herein are methods for a novel bead-based next-generation “X-aptamer” selection scheme that extends aptamer technology to include X-modified bases, thus resulting in X-aptamers, at any position along the sequence because the aptamers are chemically synthesized via a split-pool scheme on individual beads. Also provides are application to a wide range of commonly used DNA modifications, including, but not limited to, monothioate and dithioate backbone substitutions. This new class of aptamer allows chemical modifications introduced to any of the bases in the aptamer sequence as well as the phosphate backbones and can be extended to other carbohydrate-based systems. | 2014-04-10 |
20140100121 | MUTATIONAL ANALYSIS OF PLASMA DNA FOR CANCER DETECTION - A frequency of somatic mutations in a biological sample (e.g., plasma or serum) of a subject undergoing screening or monitoring for cancer, can be compared with that in the constitutional DNA of the same subject. A parameter can derived from these frequencies and used to determine a classification of a level of cancer. False positives can be filtered out by requiring any variant locus to have at least a specified number of variant sequence reads (tags), thereby providing a more accurate parameter. The relative frequencies for different variant loci can be analyzed to determine a level of heterogeneity of tumors in a patient. | 2014-04-10 |
20140100122 | METHODS, COMPOSITIONS AND SYSTEMS FOR SAMPLE DEPOSITION - Methods, compositions, systems, apparatus, and kits are provided for depositing samples onto surfaces. The samples can include one or more particles, and the surface can include one or more reaction chambers. In some embodiments, the depositing can include the use of companion particles in combination with sample particles. | 2014-04-10 |
20140100123 | MICROVESSELS, MICROPARTICLES, AND METHODS OF MANUFACTURING AND USING THE SAME - A plurality of isolated microvessels including a plurality of encoded microvessels each having a microbody and a reservoir core. The microbody is configured to separate a biological or chemical substance in the reservoir core from an ambient environment surrounding the microbody. The microbody includes a transparent material that at least partially surrounds the reservoir core and facilitates detection of an optical characteristic of the substance within the reservoir core. The microbody of each microvessel includes an identifiable code that distinguishes individual microvessels of the plurality of encoded microvessels from each other. The plurality of isolated microvessels also includes a plurality of compartments each configured to separate individual microvessels of the plurality of encoded microvessels from each other. | 2014-04-10 |
20140100124 | DIAGNOSTIC MIRNAS FOR DIFFERENTIAL DIAGNOSIS OF INCIDENTAL PANCREATIC CYSTIC LESIONS - Embodiments concern methods and compositions for characterizing or evaluating neoplastic pancreatic cells using miRNAs that are measured and used in calculations to determine a risk score for a patient. | 2014-04-10 |
20140100125 | Methods, Kits and Compositions for Determining Severity and Survival of Heart Failure in a Subject - The application provides a method of determining a severity of heart failure in a human test subject, by determining a level of RNA encoded by one or more heart failure marker genes in blood of the test subject compared to controls. The application also provides a method of determining survival outcome and allows the ranking of test subjects based on the level of RNA encoded by one or more survival associated genes. | 2014-04-10 |
20140100126 | Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data - Provided herein are methods for determining the ploidy state of one or more chromosome in a developing fetus. The subject methods provide for increase accuracy by utilizing information about the mosaicism level of one or more chromosomes of interest in the mother of fetus. The mosaicism level of one or more chromosomes of interest is determine for the maternal tissue that is used as the source of nucleic acid for genetic analysis that are used to determine the ploidy state of the fetal chromosome or chromosomes of interest. For example, if 5% white blood cells of mother are missing a copy of the X chromosome, this information can be used when determining fetal ploidy level, rather than operating under the assumption that the maternal X chromosome are present in two copies. Utilization of the mosaicism data can be used to increase the reliability and accuracy of the determination of the ploidy state of a chromosome of interest. | 2014-04-10 |
20140100127 | LIVER CANCER DIAGNOSIS MARKER AND USE THEREOF - A marker for the detection of liver cancer and application of the marker thereof. The application includes use of cytochrome p450 family 17 subfamily A polypeptide 1 (CYP17A1 protein) in the preparation of diagnostic reagents or kits for the detection of liver cancer kit. Studies have shown that CYP17A1 expression levels are higher in liver cancer tissues than in the adjacent healthy tissues, and the amount of CYP17A1 in sera of liver patients is significantly higher than that of healthy human population. Therefore, CYP17A1 can be used as a marker for the diagnosis of liver cancer (especially serological diagnosis). | 2014-04-10 |
20140100128 | USE OF MARKERS IN THE IDENTIFICATION OF CARDIOTOXIC AGENTS AND IN THE DIAGNOSIS AND MONITORING OF CARDIOMYOPATHY AND CARDIOVASCULAR DISEASE - The invention provides methods for the diagnosis and prognosis of cardiovascular disease, and for monitoring of the treatment of cardiovascular disease, including heart failure and cardiomyopathy. The invention further provides methods for identifying an agent for treating cardiomyopathy or heart failure, for identifying a cardiotoxic agent, and for identifying a rescue agent to reduce or prevent drug-induced toxicity, by using one or more biomarkers selelcted from the group consisting of CCDC47, HMOX1, PTX3, PAI1, IL27, IGFBP7, Emmprin, CFL2, EDIL3, NUCB1, PE D18:0-20:3/D18:1-20:2/D16:0-22:3; PE D18:0-22:5/D18:1-22:4; PE D16:1-22:6; PE P18:1-18:1/P18:0-18:2/P16:0-20:2; LPC 20:3; and PC-LI-183-D18:22-22:6, or any of the other biomarkers provided herein. The invention further provides kits for practicing the methods of the invention. | 2014-04-10 |
20140100129 | METHOD OF THERAPY AND DIAGNOSIS OF ATHEROSCLEROSIS - There is provided a method of therapy of atherosclerosis, by providing microRNA let-7g, an analogue thereof or modified let-7g to organisms to inhibit the expression of lectin-like oxidized low density lipoprotein receptor-1 (LOX-1), and the binding of LOX-1 and oxidized low-density lipoprotein (oxLDL), so as to block the pathogenesis of atherosclerosis. Also, a method of diagnosis of atherosclerosis comprises determining the levels of microRNA let-7g in serum or plasma samples of organisms, in which the levels of microRNA let-7g is estimated in individuals with atherosclerosis as compared to individuals without atherosclerosis. | 2014-04-10 |
20140100130 | Methods and Compositions for the Diagnosis of Ovarian Cancer - A diagnostic reagent or device comprises at least one ligand capable of specifically complexing with, binding to, or quantitatively detecting or identifying the biomarker chloride intracellular channel protein 4 (CLIC4) or an isoform, pro-form, modified molecular form including posttranslational modification, or unique peptide fragment or nucleic acid fragment thereof. An alternative diagnostic reagent or device comprises ligand or ligands capable of specifically complexing with, binding to, or quantitatively detecting or identifying multiple tropomyosin biomarkers. Optionally, such reagent or device includes a signaling molecule and/or a substrate on which the ligand is immobilized. Other reagents and methods of diagnosing ovarian cancer include use of CLIC4 ligands and/or multiple tropomyosin ligands with an additional ovarian cancer biomarker. For example, CLIC4 combined with one or more of CLIC1 and/or one or multiple members of the tropomyosin family, e.g., TPM1, TPM2, TPM3 or TPM4, and further optionally including CTSD-30 kDa and/or PRDX-6, among other ovarian cancer biomarkers can form a characteristic diagnostic pattern or profile of expression that is diagnostic of the disease. Still other embodiments are described. | 2014-04-10 |
20140100131 | Methods and Reagents for Target Isolation from a Sample - The present invention provides methods and kits for isolating a target of interest from a sample, where the methods involve use of nucleic acid strand displacement technology. | 2014-04-10 |
20140100132 | PROCESSES FOR DETECTING OR QUANTIFYING MORE THAN ONE NUCLEIC ACID IN A LIBRARY - This invention provides novel compositions and processes for analyte detection, quantification and amplification. Nucleic acid arrays and libraries of analytes are usefully incorporated into such compositions and processes. Universal detection elements, signaling entities and the like are employed to detect and if necessary or desirable, to quantify analytes. Amplification of target analytes are also provided by the compositions and processes of this invention. | 2014-04-10 |
20140100133 | Methods for Diagnosing Breast Cancer Using MicroRNAs - Described herein are methods for diagnosing breast cancer using microRNAs. Also described are methods and compositions for the diagnosis and treatment of solid cancers. Methods of identifying inhibitors of tumorigenesis are also provided. | 2014-04-10 |
20140100134 | METHODS FOR NON-INVASIVE PRENATAL PLOIDY CALLING - The present disclosure provides methods for determining the ploidy status of a chromosome in a gestating fetus from genotypic data measured from a sample of DNA from the mother of the fetus and from the fetus, and from genotypic data from the mother and optionally also from the father. The ploidy state is determined by using a joint distribution model to create a set of expected allele distributions for different possible fetal ploidy states given the parental genotypic data, and comparing the expected allelic distributions to the pattern of measured allelic distributions measured in the mixed sample, and choosing the ploidy state whose expected allelic distribution pattern most closely matches the observed allelic distribution pattern. In an embodiment, the mixed sample of DNA may be preferentially enriched at a plurality of polymorphic loci in a way that minimizes the allelic bias. | 2014-04-10 |
20140100135 | DETECTION OF NUCLEIC ACID SEQUENCE DIFFERENCES USING THE LIGASE DETECTION REACTION WITH ADDRESSABLE ARRAYS - The present invention describes a method for identifying one or more of a plurality of sequences differing by one or more single base changes, insertions, deletions, or translocations in a plurality of target nucleotide sequences. The method includes a ligation phase, a capture phase, and a detection phase. The ligation phase utilizes a ligation detection reaction between one oligonucleotide probe, which has a target sequence-specific portion and an addressable array-specific portion, and a second oligonucleotide probe, having a target sequence-specific portion and a detectable label. After the ligation phase, the capture phase is carried out by hybridizing the ligated oligonucleotide probes to a solid support with an array of immobilized capture oligonucleotides at least some of which are complementary to the addressable array-specific portion. Following completion of the capture phase, a detection phase is carried out to detect the labels of ligated oligonucleotide probes hybridized to the solid support. | 2014-04-10 |
20140100136 | ISOLATION AND CHARACTERIZATION OF PATHOGENS - Methods of the invention generally involve using magnetic particles to isolate low levels of pathogens from a samples and identifying genes expressed by those pathogen. In one aspect, the method includes obtaining a sample comprising a pathogen, forming magnetic particle/target complexes, separating the magnetic particle/target complexes using magnetic fields, and determining an expression profile of a nucleic acid derived from the target. | 2014-04-10 |
20140100137 | MARKERS FOR IMPAIRED BONE FRACTURE HEALING - The present application discloses particularly interleukin-8 (IL-8) as a novel biomarker for the prediction, diagnosis, prognosis and/or monitoring of impaired bone fracture healing; and related methods, uses and kits. | 2014-04-10 |
20140100138 | MECHANICAL STRESS RESPONSE ANALYSIS OF CELLS AND TISSUES - A method and device are disclosed for inducing mechanical stress in a cellular sample to evaluate mechanotransduction in the cellular sample. In one embodiment, the mechanical stress is induced by generating a microcavitation bubble in the cellular sample using a pulsed energy. The microcavitation bubble creates a microtsunami, which provides a transient, impulsive mechanical stress on the cellular sample, forming a gradient of effects at distances away from the microcavitation bubble. | 2014-04-10 |
20140100139 | METHOD FOR SCHEDULING SAMPLES IN A COMBINATIONAL CLINICAL ANALYZER - A method for scheduling the order of analysis of multiple samples in a combinational clinical analyzer performing a plurality of different analytical tests, includes the steps of: loading multiple samples in random order into a combinational clinical analyzer; defining the test requirements of the multiple samples; transferring said test requirements to a flexible scheduling algorithm; and generating a schedule specifying the start times of each required test for each of said multiple samples that minimizes or maximizes a predefined objective function. In a preferred embodiment, the objective function is the makespan or weighted makespan. | 2014-04-10 |
20140100140 | METHODS OF LOCALIZING NUCLEIC ACIDS TO ARRAYS - Methods are disclosed relating to localizing nucleic acids to arrays such as silane-free arrays, and of sequencing the nucleic acids localized thereby. | 2014-04-10 |
20140100141 | Compartementalized integrated biochips - An integrated microfluidic biochip is provided that includes a microfluidic device, where the microfluidic device includes hollow structures, where at least one the hollow structure includes an output at a bottom surface of the microfluidic device, and a sensor plate, where the sensor plate comprises a plurality of independent surface sensors, where the microfluidic device is sealably attachable to the sensor plate, where the hollow structure output abuts the surface sensor when the microfluidic device is attached to the sensor plate. | 2014-04-10 |
20140100142 | TRACEABLE POLYMERIC SCALE INHIBITORS AND METHODS OF USING SUCH SCALE INHIBITORS - A traceable polymeric scale inhibitor comprises a traceable phosphinate moiety and a scale inhibiting moiety including carboxylate functionality. The polymeric scale inhibitor may be derived from polymerization of a mixture comprising a phosphinate compound and a vinyl-carboxylate monomer. The traceable polymeric scale inhibitor may be used for oilfield applications. A method of reducing scale formation comprises treating the fluid subjected to scale formation with the traceable polymeric scale inhibitor. The method provides a means to determine when additional treatment of scale inhibitors is needed, which conduit or wellbore needs additional treatment of scale inhibitor, and how much additional scale inhibitor is needed in the repeat treatment to provide effective inhibition of scale formation. | 2014-04-10 |
20140100143 | SYSTEMS AND METHODS OF TREATING WATER USED FOR HYDRAULIC FRACTURING - A system and method of treating a fluid to be used for hydraulic fracturing adds an effective amount of chlorine dioxide to the fluid to act as a biocide that kills harmful bacteria. A system for adding chlorine dioxide to the fluid can continuously add chlorine dioxide to an incoming flow of the fluid to produce a continuous flow of treated fluid. | 2014-04-10 |
20140100144 | Maintenance-free Slide Bearing with a Combined Adhesive Sliding Layer - Slide bearings and methods of producing slide bearings are disclosed. The slide bearing has a metal support and a sliding layer. No other layer is in contact with the sliding layer. The sliding layer is applied directly to the metal support. The sliding layer comprises a mixture of at least two polymers P1 and P2, wherein P1 is a fluoropolymer. P2 is a non-fluorinated thermoplastic polymer. | 2014-04-10 |
20140100145 | Lubricant Composition and Method of Forming - The present disclosure describes compositions and a method for forming such compositions. More specifically, inorganic microparticles and surface modified silica nanoparticles are mixed to form a composition. The surface modified silica nanoparticles are present in the composition in an amount sufficient to decrease the coefficient of friction relative to a comparable composition that is free of surface modified silica nanoparticles. | 2014-04-10 |
20140100146 | LUBRICATING OIL COMPOSITION - A lubricating oil composition having a sulfur content of up to about 0.4 wt. % and a sulfated ash content of up to about 0.5 wt. % as determined by ASTM D874 is disclosed which comprises (a) a major amount of an oil of lubricating viscosity; (b) at least one oil-soluble or dispersed oil-stable boron-containing compound having no more than about 400 ppm of boron; and (c) at least one oil-soluble or dispersed oil-stable molybdenum-containing compound having at least about 1100 ppm of molybdenum, based upon the total mass of the composition; wherein the lubricating oil composition has a ratio of sulfur to molybdenum of less than or equal to about 4:1. | 2014-04-10 |
20140100147 | LUBRICANT ADDITIVE AND LUBRICANT OIL COMPOSITION - A lubricant additive containing (A) a nitrogen-containing compound represented by the general formula (1) and (B) a borate ester compound represented by the general formula (2) and/or a borate ester compound represented by the general formula (3); and a lubricant oil composition containing the lubricant additive and a lubricant base oil, the lubricant additive and the lubricant oil composition containing an oiliness agent-type friction modifier that can exhibit a better friction reduction effect than that of conventional oiliness agent-type friction modifiers under a wider range of friction conditions. | 2014-04-10 |
20140100148 | LUBRICATING OIL COMPOSITION - The present invention provides a lubricating oil composition exhibit excellent friction reduction properties with a small amount of molybdenum. The lubricating oil composition comprises a lubricating base oil, (A) a phosphoric acid ester metal salt represented by formula (1) and (B) an organic molybdenum compound with a ratio of molybdenum to sulfur of 1:3.5 or greater. (In formula 1, R | 2014-04-10 |
20140100149 | LOW POUR POINT LUBRICANT BASE STOCK - Disclosed is a lubricant base stock, exhibiting a combination of high flash point, low evaporation loss, high viscosity and unexpectedly exceptionally low pour point and high viscosity index value. Said lubricant base stock comprises at least one ester between 2-propylheptanoic acid and at least one 2,2-substituted 1,3-propanediol and/or at least one dimer, trimer or polymer thereof and/or at least one alkoxylated species of a said 2,2-substituted 1,3-propanediol or a said dimer, trimer or polymer thereof. | 2014-04-10 |
20140100150 | ESTOLIDE DERIVATIVES USEFUL AS BIOLUBRICANTS - A composition comprising a mixture of esters prepared by a three-step process comprising the steps of a oligomerization, a transesterification, and a capping. The composition is useful in a variety of applications, including as a biolubricant having a high level of renewable carbons, and may exhibit particularly desirable properties relating to pour point, thermo-oxidative stability, and viscometric behavior due to reduced or eliminated levels of unsaturation in the final double esters. | 2014-04-10 |
20140100151 | Stripping and Cleaning Compositions for Removal of Thick Film Resist - Stripping and cleaning compositions suitable for the removal of film resists include about 2-55% by weight of at least one alkanolamine or at least one morpholine or mixtures thereof; about 20-94% by weight of at least one organic solvent; and about 0.5-60% by weight water based on the total weight of the composition. | 2014-04-10 |
20140100152 | Coated Bleach Materials - The invention relates to particles of bleach material that comprise at least two coating layers. At least one of the coating layers comprises a sugar compound and at least one other coating layer comprises a polymer. The invention also relates to detergent compositions containing the coated particles. | 2014-04-10 |
20140100153 | PRE-SOAK TECHNOLOGY FOR LAUNDRY AND OTHER HARD SURFACE CLEANING - The invention relates to methods and compositions that may be used in a pre-soak system which maintains whitening and eliminates concerns of chlorine stability. The compositions and methods may be used for laundry, toilet bowl cleaners, ware wash cleaners, floor cleaners and the like. The system and compositions are particularly suited for laundry in a pre-soak system that includes the use of a “strainer” or basket for accomplishing the pre-soak step. Heavier soils fall to the bottom of the receptacle while greasy soils float to the top. | 2014-04-10 |
20140100154 | Prodrugs of Peptide Epoxy Ketone Protease Inhibitors - This disclosure features compounds that are useful as pro-drugs of epoxy ketone protease inhibitors. | 2014-04-10 |
20140100155 | COMBINATION THERAPY AND KIT FOR THE PREVENTION AND TREATMENT OF CYSTIC FIBROSIS - A combination therapy and kit including an agent that inhibit the interaction between CAL and mutant CFTR proteins, in combination with a CFTR corrector, CFTR potentiator, mucolytic, anti-inflammatory agent or a combination thereof are provided as is a method for preventing or treating cystic fibrosis. | 2014-04-10 |
20140100156 | EXENDIN-4 DERIVATIVES AS DUAL GLP1/GLUCAGON AGONISTS - The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake. | 2014-04-10 |
20140100157 | METHOD OF INHIBITING CLOSTRIDIUM DIFFICILE BY ADMINISTRATION OF ORITAVANCIN - Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against both a vegetative form of | 2014-04-10 |
20140100158 | Use of Ultrarapid Acting Insulin - Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day. | 2014-04-10 |
20140100159 | USE OF RELAXIN TO RESTORE MATERNAL PHYSIOLOGY IN PREGNANCIES CONVEIVED BY ASSISTED REPRODUCTIVE TECHNOLOGIES - The subject invention relates to methods for improving a subject's vasculature to normalize maternal hemodynamics, particularly in subjects attempting to conceive via assisted reproductive technologies, and comprises increasing relaxin levels in a subject or increasing any one or more of: relaxin synthesis, relaxin receptor synthesis, relaxin binding to the relaxin receptor, or relaxin receptor activity. | 2014-04-10 |
20140100160 | NOVEL USE OF C-TERMINAL DOMAIN OF IGFBP-5 COMPRISING HEPARIN-BINDING DOMAIN AS AN ANGIOGENESIS INHIBITOR - The present invention relates to a pharmaceutical composition for inhibiting angiogenesis comprising an isolated peptide comprising the heparin-binding domain of insulin-like growth factor-binding protein-5 (IGFBP-5), a method for inhibiting angiogenesis using the peptide, a pharmaceutical composition for the prevention or treatment of cancer comprising the peptide, a method for treating cancer using the peptide, a novel angiogenesis-inhibiting peptide derived from heparin-binding domain of IGFBP-5, a polynucleotide encoding the peptide, an expression vector comprising the polynucleotide and a transformant comprising the vector. | 2014-04-10 |
20140100161 | System and Method for Multiphasic Release of Growth Factors - A system for multiphasic delivery of at least one growth factor at a treatment site comprises a delivery vehicle for releasing at least one growth factor in an initial release profile and a carrier for releasing at least one growth factor in a sustained release profile. The initial release profile releases at least one growth factor over a period of hours to days, wherein the growth factor is released in a large amount initially, with the remainder being released in progressively lower amounts. The sustained release profile releases at least one growth factor over a period of days to weeks, wherein the growth factor is released at a generally constant amount over such period. The system of the invention is particularly suited for applications on bioimplants. The invention also comprises methods and kits for multiphasic delivery of at least one growth factor. | 2014-04-10 |
20140100162 | PREVENTION OF KIDNEY INJURY DISEASE - The present invention relates to a dosage regime of a peptide analogues of [alpha]-melanocyte-stimulating hormone ([alpha]-MSH), which possesses an increased efficacy compared to the native [alpha]-MSH peptide in the treatment or prevention of kidney injury or disease. | 2014-04-10 |
20140100163 | NON-PEPTIDE AGONISTS AND ANTAGONISTS OF ADRENOMEDULLIN AND GASTRIN RELEASING PEPTIDE - This invention relates, e.g., to methods for inhibiting or stimulating an activity of an adrenomedullin (AM) or gastrin releasing peptide (GRP) peptide hormone, comprising contacting the peptide with a small molecule, non-peptide, modulatory agent of the invention. Complexes of these modulatory agents with other components, such as the peptides or blocking antibodies specific for the peptides, are also described, as are pharmaceutical compositions comprising the modulatory agents, and methods for using the modulatory agents to diagnose or treat patients. | 2014-04-10 |
20140100164 | PEPTIDE MODULATORS OF ANGIOGENESIS AND USE THEREOF - The invention generally features compositions and methods that are useful for modulating blood vessel formation, as well as methods that provide for the systematic and efficient identification of angiogenesis modulators. As described in more detail below, a systematic computational methodology based on bioinformatics was used to identify novel peptide modulators of angiogenesis that have been characterized in vitro and/or in vivo. | 2014-04-10 |
20140100165 | PREVENTION OF KIDNEY INJURY OR DISEASE - The present invention relates to a dosage regime of a peptide analogues of [alpha]-melanocyte-stimulating hormone ([alpha]-MSH), which possesses an increased efficacy compared to the native [alpha]-MSH peptide in the treatment or prevention of kidney injury or disease. | 2014-04-10 |
20140100166 | METHODS FOR THE PREVENTION OR TREATMENT OF HEART FAILURE - The disclosure provides methods of preventing or treating heart failure in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof. | 2014-04-10 |
20140100167 | ASSESSMENT OF CARDIAC HEALTH AND THROMBOTIC RISK IN A PATIENT - The invention features methods and compositions for assessing risk, particularly immediate risk, of thrombotic events in patients with suspected or known vascular disease, and more particularly to assessing risk of thrombotic events in patients with coronary artery disease, particularly acute myocardial infarction, stroke, unstable angina, stable angina, or restenosis. Risk of thrombosis can be assessed by analysis of platelet reactivity and/or velocity of thrombin or fibrin formation, and determining whether the patient has a score associated above a risk threshold value. In other embodiments, risk of thrombosis in a patient is evaluated in the context of a profile generated from values obtained from one or more assays that evaluate various factors associated with thrombosis and/or atherosclerosis. | 2014-04-10 |
20140100168 | Prodrugs of Peptide Epoxy Ketone Protease Inhibitors - This disclosure features compounds that are useful as pro-drugs of epoxy ketone protease inhibitors. | 2014-04-10 |
20140100169 | COMPOUNDS FOR ENZYME INHIBITION - One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention. | 2014-04-10 |
20140100170 | PLANT-DERIVED ELASTIN BINDING PROTEIN LIGANDS AND METHODS OF USING THE SAME - The present invention describes novel plant derived elastin-like peptides and peptidomimetics that may serve as functional ligands for elastin receptors and stimulate elastogenesis. The novel plant derived peptides provide an alternative (non-animal derived) source of GXXPG (SEQ ID NO. 2) containing peptides. The present invention also describes therapeutic compositions containing novel plant derived peptides or peptidomimetics useful in stimulating elastogenensis and capillary dilatation. The therapeutic compositions of the present invention that comprise novel plant derived peptides or peptidomimetics may be combined with other therapeutic agents. | 2014-04-10 |
20140100171 | Methods of Improving the Appearance of Aging Skin - A method of improving the appearance of aging skin includes applying to skin tissue having dullness or lack of radiance, or eleven lines, marionette lines, or horizontal forehead lines, or sagging skin, a composition containing S-acyl glutathione derivative having unsaturated or saturated C | 2014-04-10 |
20140100172 | Cancer Imaging and Treatment - Provided herein are compounds useful for diagnostic imaging and/or therapeutic purposes. Each compound comprises a ligand for the chemokine receptor CXCR4, which has a binding affinity for the CXCR4 receptor, measured as IC50 in the presence of | 2014-04-10 |
20140100173 | Nitrile-containing enzyme inhibitors and ruthenium complexes thereof - The invention provides nitrile-containing protease inhibitors caged to ruthenium compounds. The nitrile-caged ruthenium compounds provide inactivated inhibitors that can be delivered to surface or site for activation, for example, but exposure to light. The invention also provides methods for delivering protease inhibitors to subjects for the therapeutic treatment of conditions such as cancer. | 2014-04-10 |
20140100174 | Treatment for Cancer - Treatment for Cancer Using A Preparation containing a combination of one or more Natural or Synthetic or a Combination of Natural and Synthetic Boswellic Acids and one or more Natural or Synthetic or a Combination of Natural and Synthetic Cytokinins such as Kinetin, Kinetin Riboside and other Cytokinins and (the Preparation) could also contain one or more Natural or Synthetic or a Combination of Natural and Synthetic plant growth hormones such as Auxins in any percentage ratio for Treating Cancer. | 2014-04-10 |
20140100175 | Insecticidal Agents and Uses Thereof - The present invention provides insecticidal lipids and lipid fractions from fungi of the phylum Ascomycota, together with compositions comprising such lipids and lipid fractions and methods of preparing same. Methods for the biological control of insects, such as phytopathogenic insects, using the lipids and lipid fractions or compositions comprising said lipids optionally together with one or more insecticidal or entomopathogenic agents including entomopathogenic fungi, are also provided. | 2014-04-10 |
20140100176 | L-SUGAR COLON CLEANSING AGENT AND USES THEREOF - Disclosed is L-glucose monohydrate and compositions thereof. Also disclosed are methods for making L-glucose monohydrate and compositions thereof. Further disclosed are methods for colonic cleansing using L-sugars, such as L-glucose monohydrate, and compositions and kits useful for colonic cleansing. | 2014-04-10 |
20140100177 | COMPOSITION COMPRISING CASHEW APPLE EXTRACT - The invention concerns a cashew apple extract and a composition comprising a cashew apple extract and optionally a carrier, in particular for use for allowing reduction of body weight gain or limitation of increasing body weight, reduction or limitation of fat storage, of fatty liver, of liver triglycerides level, of hypertriglyceridemia, of glycemia level, of insulinemia, of insulin resistance, and/or of one or several factors of metabolic syndrome. | 2014-04-10 |
20140100178 | COMPOSITION AND METHODS FOR SITE-SPECIFIC DRUG DELIVERY TO TREAT MALARIA AND OTHER LIVER DISEASES - A system for selectively delivering drugs to target tissues is provided. The system includes a drug-linker-saccharide-drug conjugate (D-L-A-D1). The linker includes a functional group that is recognized and cleaved by enzyme in the target phases. The recognition segment is preferably a malaria drugs. The carrier is preferably hydrophilic, biodegradable and biocompatible particle. Any drug may be delivered using a conjugate prepared according to the invention. | 2014-04-10 |
20140100179 | NOVEL UREA COMPOUNDS - The present invention provides a compound of Formula I: | 2014-04-10 |
20140100180 | TOPICAL PHARMACEUTICAL COMPOSITION BASED ON SEMIFLUORINATED ALKANES - The invention provides liquid or semi-solid pharmaceutical compositions for topical administration comprising a semifluorinated alkane. The compositions are useful for the delivery of active ingredients into the deep layers of the skin or skin appendages. Various active ingredients may be incorporated, such as immunosuppressants, antiinfectives, antifungal agents, antiinflammatory agents, and retinoids. | 2014-04-10 |
20140100181 | TOPICAL PHARMACEUTICAL COMPOSITION CONTAINING A WATER-SENSITIVE ACTIVE PRINCIPLE - A topical pharmaceutical composition including, as a pharmaceutical active agent, a water-sensitive compound in a solubilised form in a physiologically acceptable medium is described. A method for preparing such a composition, and uses thereof in dermatology are also described. | 2014-04-10 |
20140100182 | Nanogel-Mediated Drug Delivery - Provided herein are methods of inhibiting proliferation of one or more tumor cells comprising contacting the one or more tumor cells with a composition comprising one or more epigenetic drugs that inhibit one or more epigenetic mechanisms of the tumor cells, wherein the one or more epigenetic drugs are encapsulated in a nanogel. The invention is also directed to methods of treating a tumor, metastasis of a tumor or a combination thereof in an individual in need thereof. The invention is also directed to a method of sequentially delivering one or more epigenetic drugs that alter one or more epigenetic mechanisms of a tumor cell and one or more chemotherapeutic drugs to an individual that has a tumor. Compositions which comprise one or more epigenetic drugs that alter one or more epigenetic mechanisms of a tumor cell, wherein the one or more epigenetic drugs are encapsulated in a nanogel. | 2014-04-10 |
20140100183 | CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC AGENTS FOR CNS CONDITIONS - The present invention concerns compositions, methods and/or apparatus of central administration of various CNS-active agents. In particular embodiments, intrathecal administration is advantageous for decreasing the systemic concentrations of CNS agent, thereby decreasing side effect toxicity, while allowing more effective delivery of the agent to the site of action, simultaneously decreasing the dosage delivered to the subject. In particular embodiments, ICV delivery may be of use for patients who have previously proven to be refractory to systemic administration of CNS agents, in some cases due to systemic side effects, or for those patients whose symptoms are of sufficient severity to warrant more aggressive therapeutic intervention. ICV administration allows not only lower systemic concentration but also higher therapeutically effective concentration within the CNS. | 2014-04-10 |
20140100184 | SELECTIVE INHIBITORS OF HISTONE METHYLTRANSFERASE DOT1L - Structure and mechanism based design was used to design potent ribose containing inhibitors of DOT1L with IC | 2014-04-10 |
20140100185 | UNIT DOSAGE OF APADENOSON - The present invention provides a unit dosage of Apadenoson, a pharmacological stress agent, and use of the same as a pharmacologic agent for myocardial perfusion imaging. | 2014-04-10 |
20140100186 | METHOD TO IMPROVE ANTIVIRAL ACTIVITY OF NUCLEOTIDE ANALOGUE DRUGS - A method of modifying a nucleotide or a nucleotide analogue to increase its overall effectiveness in treating an antiviral disease is provided. In some cases, a compound comprising a base, sugar, phosphonate moiety, and amino acid residue is provided, where the base-sugar may be a nucleoside, and the amino acid residue may be a tyrosine residue. In certain cases, the tyrosine residue contains a long chain alkyl group on the carboxamide group of the residue. Methods of inhibiting viral replication and methods of treating a viral infection are also provided. | 2014-04-10 |
20140100187 | COMBINATIONS OF SAPACITABINE OR CNDAC WITH DNA METHYLTRANSFERASE INHIBITORS SUCH AS DECITABINE AND PROCAINE - A first aspect of the invention relates to a combination comprising a DNA methyltransferase inhibitor and 1-(2-C-cyano-2-dioxy-β-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof. A second aspect of the invention relates to a pharmaceutical product comprising a DNA methyltransferase inhibitor and 1-(2-C-cyano-2-dioxy-β-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, as a combined preparation for simultaneous, sequential or separate use in therapy. A third aspect of the invention relates to a method of treating a proliferative disorder, said method comprising simultaneously, sequentially or separately administering a DNA methyltransferase inhibitor and 1-(2-C-cyano-2-dioxy-β-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, to a subject. | 2014-04-10 |
20140100188 | PHENOTYPING TUMOR-INFILTRATING LEUKOCYTES - The present disclosure relates to an immune signature of tumor infiltrating leukocytes. In particular, the disclosure provides methods and kits for determining the immune signature of tumor infiltrating leukocytes for use in assessing risk of cancer recurrence and long term survival, and for developing a treatment regimen for a cancer patient. | 2014-04-10 |
20140100189 | CARBOHYDRATES MIXTURE - A carbohydrate mixture for dietetic foods and pharmaceuticals is provided. The carbohydrate mixture comprises two different, substantially soluble carbohydrate components A and B, which remain undigested in the gastrointestinal tract and enter the large intestine without being resorbed. Carbohydrate component A may comprise at least one monosaccharide or of at least one oligosaccharide (disaccharide to hexasaccharide) or a mixture of two or more of these saccharides. Carbohydrate component B may comprise a polysaccharide (from heptasaccharide onwards) or a mixture of two or more polysaccharides. Carbohydrate component A=5 to 95 wt-% and carbohydrate component B=5 to 95 wt-% of the sum of the carbohydrate components A+B (=100 wt-%), and at least 80 wt-% of the carbohydrates/saccharides of both carbohydrate components have a prebiotic effect. The carbohydrate mixtures have not only a nutritive effect but they also stimulate health-promoting microorganisms present in the natural flora of the large intestine. | 2014-04-10 |
20140100190 | USE OF LIPID CONJUGATES IN CYSTIC FIBROSIS AND APPLICATIONS THEREOF - This invention provides for the use of compounds represented by the structure of the general formula (A): | 2014-04-10 |
20140100191 | Vesicular Formulations - Disclosed herein are vesicular formulations that include one or more phospholipids and one or more surfactants and in certain embodiments the use of such formulations for the delivery of fatty acids for the treatment of disorders such as, fatty acid metabolic disorders, including essential fatty acid deficiency; pain or inflammation or osteoarthritis, more specifically for the treatment of deep tissue pain; asthma, bronchospasm, atherothrombatic cardiovascular disorders, avenous thrombatic disorders, inflammatory dermatoses disorders (e.g., atopic eczema, dishydrotic hand eczema, plaque type psoriasis, seborrheic eczema, and acne vulgaris), and dysmenorrhea. | 2014-04-10 |
20140100192 | Pharmaceutical Formulation Containing Choline Alfoscerate - The present invention provides choline alfoscerate-containing pharmaceutical preparations which have improved storage-stability and are easily taken. The present invention also provides a method for manufacturing pharmaceutical preparations comprising choline alfoscerate, which is easy and simple and is performed by normal manufacturing equipments. | 2014-04-10 |
20140100193 | Diazonamide Analogs - Diazonamide analogs having anti-mitotic activity, useful for the treatment of cancer and other proliferative disorders, and related pharmaceutical compositions are provided. | 2014-04-10 |
20140100194 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS - The invention is directed to TRPM8 antagonists of Formula (I). More specifically, the present invention relates to certain novel compounds, methods for preparing compounds, compositions, intermediates and derivatives thereof and methods for treating TRPM8-mediated disorders. Pharmaceutical and veterinary compositions and methods of treating pain and various other disease states or conditions using compounds of the invention are also described. | 2014-04-10 |
20140100195 | Heterobicyclic sphingosine 1-phosphate analogs - Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors. | 2014-04-10 |
20140100196 | PHYTOSANITARY MICROEMULSION AND THE PROCEDURE FOR OBTAINING IT - A phytosanitary microemulsion and procedure for obtaining it, wherein the resulting microemulsion is highly stable, with low content of surfactants, achieved due to a combination of an active ingredient, preferably cypermethrin, chlorpirifos or mixtures thereof; refined soy oil; a surfactant at a very low content due to the inclusion of soy oil; a biocide; bidistilled glycerine; xanthan gum and water until reaching the volume. | 2014-04-10 |
20140100197 | BICYCLIC 1, 2, 4-OXADIAZOLES DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS - The present invention relates to bicyclic aryl 1,2,4-oxadiazoles derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 2014-04-10 |
20140100198 | ENZYME INHIBITING COMPOUNDS AND METHODS - The invention provides compounds, compositions, and methods for studying the Rohmer pathway and for treating bacterial infections or parasitic infections. The parasitic infection can be a protozoan infection, such as malaria. The compounds and compositions can also be used as antibiotics, for example, to kill bacteria or parasites, or to inhibit bacterial or parasite growth. The invention further provides inhibitors of isoprenoid biosynthesis enzymes, and methods of inhibiting the activity of isoprenoid biosynthesis enzymes. The compounds can be, for example, alkynes or allenes that bind to a unique Fe of an Fe | 2014-04-10 |
20140100199 | SUBSTITUTED ARYL 1 ,2,4-OXADIAZOLES DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS - The present invention relates to substituted aryl 1,2,4-oxadiazoles derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 2014-04-10 |
20140100200 | METHODS OF TREATING ACNE - A method of treating acne in a human in need thereof comprising administering systemically to said human a tetracycline compound in an amount that is effective to treat acne but has substantially no antibiotic activity, without administering a bisphosphonate compound. | 2014-04-10 |
20140100201 | CONNECTIVE TISSUE MONITORING, COMPOSITIONS FOR CONNECTIVE TISSUE TREATMENT AND METHODS FOR TREATING CONNECTIVE TISSUE - Methods and computer instruction code for monitoring, screening and classifying the response to load of a connective tissue or part thereof are disclosed. The method includes the steps of obtaining or receiving an ultrasound scan of a connective tissue or part thereof and analysing the ultrasound scan to detect one or more region of differential structural disorganisation in the connective tissue or part thereof. The connective tissue or part thereof is then classified according to the detected one or more region of differential structural organisation to thereby monitor the response to load of the connective tissue or part thereof. Also disclosed are compositions and methods of treatment for a connective tissue disease or condition. | 2014-04-10 |
20140100202 | PROCESS FOR THE PREPARATION OF A METAL COMPLEX IN AN OILY ORGANIC MATRIX - A process is described for the preparation of a composition comprising a metal complex in an oily organic matrix, the latter being at the same time able to promote the formation of the complex. Said process also envisages that the complex, once formed, is not separated from said oily organic matrix, but the resulting composition is used as such, as having observed that the performances of the complex present therein is thus improved. | 2014-04-10 |
20140100203 | ONCE-A-WEEK ADMINISTRATION OF 25-HYDROXY VITAMIN D3 TO SUSTAIN ELEVATED STEADY-STATE PHARMACOKINETIC BLOOD CONCENTRATION - An oral dosage form comprising a single dose of 25-hydroxy-vitamin D | 2014-04-10 |
20140100204 | NATURAL COMBINATION HORMONE REPLACEMENT FORMULATIONS AND THERAPIES - Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone. | 2014-04-10 |
20140100205 | NATURAL COMBINATION HORMONE REPLACEMENT FORMULATIONS AND THERAPIES - Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone. | 2014-04-10 |
20140100206 | NATURAL COMBINATION HORMONE REPLACEMENT FORMULATIONS AND THERAPIES - Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone. | 2014-04-10 |
20140100207 | USE OF 19 NOR DHEA DERIVATIVES FOR ENHANCING PHYSICAL PERFORMANCE - A method is disclosed for administering a DHEA derivative or a physiologically acceptable salt, ester or ether thereof for one of decreasing body weight, reducing adipose tissue, increasing endurance, as an anti-aging compound and generating production of red blood cells. | 2014-04-10 |